{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:52:33Z","timestamp":1775253153343,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81572060"],"award-info":[{"award-number":["No.81572060"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The fusion oncoprotein Bcr-Abl is mostly located in the cytoplasm, which causes chronic myeloid leukemia (CML). After moving into the nucleus, the fusion protein can induce apoptosis of CML cells. The coiled-coil domain (CC domain) of Bcr-Abl protein plays a central role in the subcellular localization. However, how CC domain affects subcellular localization of Bcr-Abl remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Herein, the key proteins interacting with the Bcr-Abl CC domain were screened by immunoprecipitation binding mass spectrometry. The specific site of Bcr-Abl CC domain binding to target protein was predicted by Deep Viewer. Immunoprecipitation assay was used to confirmed the specific sites of protein binding. IF and western blot were used to observe the subcellular localization of target protein. Western blot was used to examine the protein changes. CCK-8, clonal formation test and FCM cycle detection were used to observe the effect of inhibitor on the proliferation ability of CML cells. FCM apoptosis detection was used to observe the level of cells apoptosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HSP90AB1 interacts with Bcr-Abl CC domain via N-terminal domain (NTD), preventing the transport of Bcr-Abl protein to the nucleus and maintaining the activation of Bcr-Abl tyrosine kinase. The nucleus-entrapped Bcr-Abl markedly inhibits the proliferation and induces apoptosis of CML cells by activating p73 and repressing the expression of cytoplasmic oncogenic signaling pathways mediated by Bcr-Abl. Moreover, the combination of 17AAG (Tanespimycin) with Leptomycin B (LMB) considerably decreased the proliferation of CML cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study provides evidence that it is feasible to transport Bcr-Abl into the nucleus as an alternative strategy for the treatment of CML, and targeting the NTD of HSP90AB1 to inhibit the interaction with Bcr-Abl is more accurate for the development and application of HSP90 inhibitor in the treatment of CML and other Bcr-Abl-addicted malignancies.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12964-021-00752-9","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T12:02:36Z","timestamp":1625313756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells"],"prefix":"10.1186","volume":"19","author":[{"given":"Yuhang","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenglan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangzhu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Mou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0549-6223","authenticated-orcid":false,"given":"Wenli","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,3]]},"reference":[{"issue":"8","key":"752_CR1","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113(8):1619\u201330.","journal-title":"Blood"},{"issue":"5405","key":"752_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290\u20133.","journal-title":"Nature"},{"issue":"3","key":"752_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172\u201383.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"752_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004;18(2):189\u2013218.","journal-title":"Leukemia"},{"issue":"2","key":"752_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1158\/2159-8290.CD-13-0235","volume":"4","author":"J Asmussen","year":"2014","unstructured":"Asmussen J, Lasater EA, Tajon C, Oses-Prieto J, Jun YW, Taylor BS, Burlingame A, Craik CS, Shah NP. MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction. Cancer Discov. 2014;4(2):200\u201315.","journal-title":"Cancer Discov"},{"issue":"2","key":"752_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/107327480901600202","volume":"16","author":"LA Hazlehurst","year":"2009","unstructured":"Hazlehurst LA, Bewry NN, Nair RR, Pinilla-Ibarz J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control. 2009;16(2):100\u20137.","journal-title":"Cancer Control"},{"issue":"11","key":"752_CR7","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1182\/blood.V88.11.4304.4304","volume":"88","author":"A Oda","year":"1996","unstructured":"Oda A, Miyakawa Y, Druker BJ, Ishida A, Ozaki K, Ohashi H, Wakui M, Handa M, Watanabe K, Okamoto S, et al. Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. Blood. 1996;88(11):4304\u201313.","journal-title":"Blood"},{"issue":"8","key":"752_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ajh.24774","volume":"92","author":"F Castagnetti","year":"2017","unstructured":"Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, et al. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. Am J Hematol. 2017;92(8):797\u2013805.","journal-title":"Am J Hematol"},{"issue":"18","key":"752_CR9","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1182\/blood-2012-04-423418","volume":"121","author":"A Hochhaus","year":"2013","unstructured":"Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013;121(18):3703\u20138.","journal-title":"Blood"},{"issue":"8","key":"752_CR10","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648\u201371.","journal-title":"Leukemia"},{"issue":"8","key":"752_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O'Hare","year":"2012","unstructured":"O\u2019Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012;12(8):513\u201326.","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"752_CR12","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Barate C, Rossi AR, Fioritoni G, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118(17):4554\u201360.","journal-title":"Blood"},{"issue":"5531","key":"752_CR13","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876\u201380.","journal-title":"Science"},{"issue":"1","key":"752_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1280","volume":"5","author":"O Hantschel","year":"2004","unstructured":"Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004;5(1):33\u201344.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"752_CR15","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.18632\/oncotarget.1339","volume":"4","author":"ZL Huang","year":"2013","unstructured":"Huang ZL, Gao M, Li QY, Tao K, Xiao Q, Cao WX, Feng WL. Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus. Oncotarget. 2013;4(12):2249\u201360.","journal-title":"Oncotarget"},{"issue":"2","key":"752_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/84683","volume":"7","author":"P Vigneri","year":"2001","unstructured":"Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7(2):228\u201334.","journal-title":"Nat Med"},{"issue":"3","key":"752_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jconrel.2009.06.026","volume":"140","author":"AS Dixon","year":"2009","unstructured":"Dixon AS, Kakar M, Schneider KM, Constance JE, Paullin BC, Lim CS. Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis. J Control Release. 2009;140(3):245\u20139.","journal-title":"J Control Release"},{"issue":"3","key":"752_CR18","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/ijms18030537","volume":"18","author":"Q Li","year":"2017","unstructured":"Li Q, Huang Z, Gao M, Cao W, Xiao Q, Luo H, Feng W. Blockade of Y177 and nuclear translocation of Bcr-Abl inhibits proliferation and promotes apoptosis in chronic myeloid leukemia cells. Int J Mol Sci. 2017;18(3):537.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"752_CR19","doi-asserted-by":"publisher","first-page":"6535","DOI":"10.1093\/emboj\/16.21.6535","volume":"16","author":"E Izaurralde","year":"1997","unstructured":"Izaurralde E, Kutay U, von Kobbe C, Mattaj IW, Gorlich D. The asymmetric distribution of the constituents of the Ran system is essential for transport into and out of the nucleus. EMBO J. 1997;16(21):6535\u201347.","journal-title":"EMBO J"},{"issue":"8","key":"752_CR20","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/leu.2015.53","volume":"29","author":"DW Woessner","year":"2015","unstructured":"Woessner DW, Eiring AM, Bruno BJ, Zabriskie MS, Reynolds KR, Miller GD, O\u2019Hare T, Deininger MW, Lim CS. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. Leukemia. 2015;29(8):1668\u201375.","journal-title":"Leukemia"},{"issue":"6","key":"752_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.leukres.2015.03.016","volume":"39","author":"M Lazenby","year":"2015","unstructured":"Lazenby M, Hills R, Burnett AK, Zabkiewicz J. The HSP90 inhibitor ganetespib: a potential effective agent for Acute Myeloid Leukemia in combination with cytarabine. Leuk Res. 2015;39(6):617\u201324.","journal-title":"Leuk Res"},{"issue":"8","key":"752_CR22","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/annonc\/mdg316","volume":"14","author":"MP Goetz","year":"2003","unstructured":"Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol. 2003;14(8):1169\u201376.","journal-title":"Ann Oncol"},{"key":"752_CR23","first-page":"757694","volume":"2015","author":"KV Khajapeer","year":"2015","unstructured":"Khajapeer KV, Baskaran R. Hsp90 inhibitors for the treatment of chronic myeloid leukemia. Leuk Res Treat. 2015;2015:757694.","journal-title":"Leuk Res Treat"},{"issue":"14","key":"752_CR24","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-16-2880","volume":"23","author":"Z Wang","year":"2017","unstructured":"Wang Z, Hu Y, Xiao D, Wang J, Liu C, Xu Y, Shi X, Jiang P, Huang L, Li P, et al. Stabilization of notch1 by the Hsp90 chaperone is crucial for T-cell leukemogenesis. Clin Cancer Res. 2017;23(14):3834\u201346.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"752_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1182\/blood-2017-10-810986","volume":"132","author":"S Bhatia","year":"2018","unstructured":"Bhatia S, Diedrich D, Frieg B, Ahlert H, Stein S, Bopp B, Lang F, Zang T, Kroger T, Ernst T, et al. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. Blood. 2018;132(3):307\u201320.","journal-title":"Blood"},{"issue":"5","key":"752_CR26","first-page":"1799","volume":"61","author":"R Nimmanapalli","year":"2001","unstructured":"Nimmanapalli R, O\u2019Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001;61(5):1799\u2013804.","journal-title":"Cancer Res"},{"issue":"18","key":"752_CR27","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.4161\/cc.6.18.4722","volume":"6","author":"C Peng","year":"2007","unstructured":"Peng C, Li D, Li S. Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle. 2007;6(18):2227\u201331.","journal-title":"Cell Cycle"},{"key":"752_CR28","first-page":"537","volume":"18","author":"MN Peiris","year":"2019","unstructured":"Peiris MN, Meyer AN, Nelson KN, Bisom-Rapp EW, Donoghue DJ. Oncogenic fusion protein BCR-FGFR1 requires BCR-mediated oligomerization and chaperonin Hsp90 for activation. Haematologica. 2019;18:537.","journal-title":"Haematologica"},{"issue":"20","key":"752_CR29","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.2174\/1381612822666160325152200","volume":"22","author":"A Haque","year":"2016","unstructured":"Haque A, Alam Q, Alam MZ, Azhar EI, Sait KH, Anfinan N, Mushtaq G, Kamal MA, Rasool M. Current understanding of HSP90 as a novel therapeutic target: an emerging approach for the treatment of cancer. Curr Pharm Des. 2016;22(20):2947\u201359.","journal-title":"Curr Pharm Des"},{"issue":"1738","key":"752_CR30","doi-asserted-by":"publisher","first-page":"20160524","DOI":"10.1098\/rstb.2016.0524","volume":"373","author":"SK Calderwood","year":"2018","unstructured":"Calderwood SK. Heat shock proteins and cancer: intracellular chaperones or extracellular signalling ligands? Philos Trans R Soc Lond B Biol Sci. 2018;373(1738):20160524.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"11","key":"752_CR31","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1021\/ci400434g","volume":"53","author":"K Blacklock","year":"2013","unstructured":"Blacklock K, Verkhivker GM. Experimentally guided structural modeling and dynamics analysis of Hsp90-p53 interactions: allosteric regulation of the Hsp90 chaperone by a client protein. J Chem Inf Model. 2013;53(11):2962\u201378.","journal-title":"J Chem Inf Model"},{"issue":"3","key":"752_CR32","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3892\/or.2017.5797","volume":"38","author":"JH Qin","year":"2017","unstructured":"Qin JH, Wang K, Fu XL, Zhou PJ, Liu Z, Xu DD, Wang YF, Yang DP, Xie QL, Liu QY. Hsp90 inhibitor induces KG-1a cell differentiation and apoptosis via Akt\/NF-kappaB signaling. Oncol Rep. 2017;38(3):1517\u201324.","journal-title":"Oncol Rep"},{"issue":"5855","key":"752_CR33","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1126\/science.1142204","volume":"318","author":"LJ Terry","year":"2007","unstructured":"Terry LJ, Shows EB, Wente SR. Crossing the nuclear envelope: hierarchical regulation of nucleocytoplasmic transport. Science. 2007;318(5855):1412\u20136.","journal-title":"Science"},{"issue":"2","key":"752_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/1535-7163.MCT-05-0409","volume":"5","author":"JV Thottassery","year":"2006","unstructured":"Thottassery JV, Westbrook L, Someya H, Parker WB. c-Abl-independent p73 stabilization during gemcitabine- or 4\u2019-thio-beta-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. Mol Cancer Ther. 2006;5(2):400\u201310.","journal-title":"Mol Cancer Ther"},{"issue":"2 Suppl 2","key":"752_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/shem.2003.50058","volume":"40","author":"SG O'Brien","year":"2003","unstructured":"O\u2019Brien SG, Deininger MW. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol. 2003;40(2 Suppl 2):26\u201330.","journal-title":"Semin Hematol"},{"issue":"24","key":"752_CR36","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315\u201326.","journal-title":"N Engl J Med"},{"issue":"18","key":"752_CR37","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1002\/pmic.201000176","volume":"10","author":"CF Lee","year":"2010","unstructured":"Lee CF, Griffiths S, Rodriguez-Suarez E, Pierce A, Unwin RD, Jaworska E, Evans CA, Whetton AD. Assessment of downstream effectors of BCR\/ABL protein tyrosine kinase using combined proteomic approaches. Proteomics. 2010;10(18):3321\u201342.","journal-title":"Proteomics"},{"issue":"6","key":"752_CR38","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1600-0854.2009.00897.x","volume":"10","author":"M Mancini","year":"2009","unstructured":"Mancini M, Veljkovic N, Corradi V, Zuffa E, Corrado P, Pagnotta E, Martinelli G, Barbieri E, Santucci MA. 14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia. Traffic. 2009;10(6):637\u201347.","journal-title":"Traffic"},{"issue":"9","key":"752_CR39","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/s41388-018-0532-5","volume":"38","author":"H Wang","year":"2019","unstructured":"Wang H, Deng G, Ai M, Xu Z, Mou T, Yu J, Liu H, Wang S, Li G. Hsp90ab1 stabilizes LRP5 to promote epithelial-mesenchymal transition via activating of AKT and Wnt\/beta-catenin signaling pathways in gastric cancer progression. Oncogene. 2019;38(9):1489\u2013507.","journal-title":"Oncogene"},{"issue":"6","key":"752_CR40","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/bjh.15715","volume":"184","author":"ML Piredda","year":"2019","unstructured":"Piredda ML, Gaur G, Catalano G, Divona M, Banella C, Travaglini S, Puzzangara MC, Voso MT, Lo-Coco F, Noguera NI. PML\/RARA inhibits expression of HSP90 and its target AKT. Br J Haematol. 2019;184(6):937\u201348.","journal-title":"Br J Haematol"},{"issue":"1","key":"752_CR41","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/jcb.25269","volume":"117","author":"J Lee","year":"2016","unstructured":"Lee J, An YS, Kim MR, Kim YA, Lee JK, Hwang CS, Chung E, Park IC, Yi JY. Heat shock protein 90 regulates subcellular localization of smads in Mv1Lu cells. J Cell Biochem. 2016;117(1):230\u20138.","journal-title":"J Cell Biochem"},{"issue":"8","key":"752_CR42","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2887","volume":"10","author":"J Trepel","year":"2010","unstructured":"Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10(8):537\u201349.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"752_CR43","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1158\/1541-7786.MCR-15-0234","volume":"13","author":"LM Butler","year":"2015","unstructured":"Butler LM, Ferraldeschi R, Armstrong HK, Centenera MM, Workman P. Maximizing the therapeutic potential of HSP90 inhibitors. Mol Cancer Res. 2015;13(11):1445\u201351.","journal-title":"Mol Cancer Res"},{"key":"752_CR44","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/978-1-4939-7477-1_29","volume":"1709","author":"A Yuno","year":"2018","unstructured":"Yuno A, Lee MJ, Lee S, Tomita Y, Rekhtman D, Moore B, Trepel JB. Clinical evaluation and biomarker profiling of Hsp90 inhibitors. Methods Mol Biol. 2018;1709:423\u201341.","journal-title":"Methods Mol Biol"},{"issue":"10","key":"752_CR45","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1172\/JCI125963","volume":"129","author":"C Pan","year":"2019","unstructured":"Pan C, Chun J, Li D, Boese AC, Li J, Kang J, Umano A, Jiang Y, Song L, Magliocca KR, et al. Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. J Clin Invest. 2019;129(10):4110\u201323.","journal-title":"J Clin Invest"},{"issue":"12","key":"752_CR46","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.1021\/acs.jmedchem.5b01106","volume":"59","author":"M Wang","year":"2016","unstructured":"Wang M, Shen A, Zhang C, Song Z, Ai J, Liu H, Sun L, Ding J, Geng M, Zhang A. Development of heat shock protein (Hsp90) inhibitors to combat resistance to tyrosine kinase inhibitors through Hsp90-kinase interactions. J Med Chem. 2016;59(12):5563\u201386.","journal-title":"J Med Chem"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-021-00752-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-021-00752-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-021-00752-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T16:30:19Z","timestamp":1699201819000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-021-00752-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1186\/s12964-021-00752-9","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,3]]},"assertion":[{"value":"27 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}